Table 1.
SARS-CoV-2 seroprevalence measured with MULTICOV-AB and the EUROIMMUNE S1 ELISA in urban and indigenous children from Colombia.
| Urban children | Indigenous children | |
|---|---|---|
| Sample collection | March 2021 | March–April 2021 |
| Total participants, n | 80 | 82 |
| Age (years), median (IQR) | 11 (9–14) | 12 (9–14) |
| Sex (female, n, %) | 43 (53.8) | 50 (61.0) |
| SARS-CoV-2 seroprevalence using MULTICOV-AB | ||
| Reactive participants, n | 17 | 28 |
| Crude seroprevalence, % (95% CI)a | 21.3 (13.2–32.1) | 34.1 (24.3–45.5) |
| Adjusted seroprevalence, % (95% CI)b | 24.1 (13.8–35.2) | 38.7 (26.8–50.7) |
| SARS-CoV-2 seroprevalence using SARS-CoV-2 ELISA EUROIMMUN | ||
| Reactive participants, n | 18 | 24 |
| Crude seroprevalence, % (95% CI)a | 22.5 (14.2–33.5) | 29.3 (20.0–40.5) |
| Adjusted seroprevalence, % (95% CI)b | 25.5 (12.9–38.9) | 34.3 (20.9–48.1) |
aBorderline ELISA results were included in the calculation as non-reactive.
bSeroprevalence was adjusted for the respective assay’s sensitivity and specificity.